- Home
- ESLA vs TVRD Comparison
ESLA vs TVRD Comparison
Compare ESLA & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESLA | TVRD |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 27.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ESLA | TVRD |
|---|---|---|
| Price | $0.77 | $2.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $8.00 | ★ $29.50 |
| AVG Volume (30 Days) | 45.3K | ★ 6.8M |
| Earning Date | 05-26-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $1.50 |
| 52 Week High | $3.15 | $43.65 |
Technical Indicators
Market Signals| Indicator | ESLA | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 34.69 | 45.16 |
| Support Level | $0.73 | $1.50 |
| Resistance Level | $1.28 | $4.27 |
| Average True Range (ATR) | 0.08 | 0.60 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 6.70 | 2.81 |
Price Performance
Historical ComparisonAbout ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.